Just five months after its acquisition of Wilson Therapeutics, Alexion Pharmaceuticals is once again bulking up its pipeline with its latest acquisition of Syntimmune in a deal worth potentially up to US$1.2 B. The acquisition gives Alexion access to Syntimmune’s lead candidate, SYNT001, a clinical-stage monoclonal antibody in development to treat diseases characterised by high levels of immunoglobulin G antibodies, including warm autoimmune hemolyticanemia, for which there are currently no approved treatments.